[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Northwestern University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":621},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,177,0,25,[9,42,76,101,129,151,171,195,224,247,273,295,315,334,362,384,405,430,459,485,509,531,560,582,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100624490","early-phase-1-bridge---blocking-receptor-of-il-1-for-donor-graft-edema-reduction-100624490",false,"NCT07410312","BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction","Inclusion Criteria:\n\n* Age 18 years or older.\n* Planning to undergo transplantation of the lung.\n* Willing and able to read, understand, and be capable of giving informed consent.\n* Use of ex vivo lung perfusion (EVLP) prior to lung transplant.\n\nExclusion Criteria:\n\n* Previous or current use of IL-1R antagonist drug.\n* Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.",[26],"Lung Transplant Recipient",[28],"lung transplant","NOT_YET_RECRUITING","2026-08-19",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":20},"2026-10-01",{"date":37,"type":20},"2027-12",{"name":39,"class":40},"Northwestern University","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":41},"100555393","northwestern-tempus-ai-enabled-electrocardiography-notable-trial-100555393","NCT06511505","NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial","NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial: A Pragmatic, Real-world Study of an Artificial-intelligence Enabled Electrocardiogram Algorithms to Improve the Diagnosis of Cardiovascular Disease","NOTABLE","Inclusion Criteria:\n\n1. Atrial fibrillation algorithm\n\n   1. Age 65 or over\n   2. ECG obtained as part of routine clinical care\n2. Structural heart disease algorithm\n\n   1. Age 40 or over\n   2. ECG obtained as part of routine clinical care\n\nExclusion Criteria:\n\n1. Atrial fibrillation algorithm\n\n   1. No history of AF\n   2. No permanent pacemaker (PPM) or implantable cardioverter defibrillator (ICD)\n   3. No recent cardiac surgery (within the preceding 30 days)\n2. Structural heart disease algorithm\n\n   1. No history of SHD\n   2. No echocardiogram within the past 1 year",true,"40 Years",{"count":53,"type":20},1000,[55],"NA","The goal of this clinical trial is to determine if a machine learning\u002Fartificial intelligence (AI)-based electrocardiogram (ECG) algorithm (rECHOmmend and ECG-AF) can identify undiagnosed cardiovascular disease in patients. It will also examine the safety and effectiveness of using this AI-based tool in a clinical setting. The main questions it aims to answer are:\n\n1. Can the AI-based ECG algorithm improve the detection of atrial fibrillation and structural heart disease?\n2. How does the use of this algorithm affect clinical decision-making and patient outcomes?\n\nResearchers will compare the outcomes of healthcare providers who receive the AI-based ECG results to those who do not. Participants (healthcare providers) will:\n\nBe randomized into two groups: one that receives AI-based ECG results and one that does not.\n\nIn the intervention group, receive an assessment of their patient's risk of atrial fibrillation or structural heart disease with each ordered ECG.\n\nDecide whether to perform further clinical evaluation based on the AI-generated risk assessment as part of routine clinical care.",[58,59,60,61],"Atrial Fibrillation","Cardiovascular Diseases","Arrhythmia","Valvular Disease",[63,64,65,66,67],"early detection","artificial intelligence","structural heart disease","atrial fibrillation","cardiac diagnostics","RECRUITING",{"date":70,"type":33},"2026-08-20",{"date":72,"type":33},"2024-09-16",{"date":74,"type":20},"2028-09",{"name":39,"class":40},{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":50,"sex":83,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100643481","ejaculatory-sparing-holep-vs-standard-holep-100643481","NCT07631286","Ejaculatory-Sparing HoLEP vs Standard HoLEP","Ejaculatory-sparing Holmium Laser Enucleation of the Prostate (HoLEP) vs Standard HoLEP: a Randomized Controlled Trial","Inclusion Criteria:\n\n\\- Patients who are sexually active with antegrade ejaculation who are undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms.\n\nExclusion Criteria:\n\n* Patients with pre-existing retrograde ejaculation\n* Patients who are not sexually active\n* Patients with indwelling urinary catheter prior to surgery, neurological disease, or history of prior prostatic\u002Furethral surgery that may impact ejaculation\n* Patients who lack decisional capacity\n* Patients unable to read\u002Fspeak English","MALE","100 Years",{"count":86,"type":20},48,[55],"The objective of this study is to compare a new surgical technique for HoLEP that will allow for sparing of ejaculation post-HoLEP.",[90,91],"Enlarged Prostate (BPH)","Enlarged Prostate With Lower Urinary Tract Symptoms",[93],"HoLEP","2026-08-18",{"date":70,"type":33},{"date":97,"type":33},"2026-06-15",{"date":99,"type":20},"2028-05",{"name":39,"class":40},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":41},"100638129","phase-1-bms-986504-in-combination-with-pemetrexed-for-the-treatment-of-metastatic-solid-tumors-with-mtap-deletion-100638129","NCT07594626","BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion","A Phase Ib\u002FII Basket Study of BMS-986504 in Combination With Pemetrexed for Metastatic Solid Tumors With MTAP Deletion","Inclusion Criteria:\n\n* COHORT A (INCLUDING SAFETY RUN IN, STAGE I AND STAGE II) AND COHORT B:\n* Patients must have pathologically or cytologically confirmed metastatic solid tumor of gastrointestinal origin with MTAP deletion including pancreatic cancer, biliary cancer, esophageal cancer and colon cancer (Cohort A) or other metastatic solid malignancy with MTAP deletion (Cohort B) confirmed by validated next generation sequencing tissue techniques only\n\n  * NOTE: Both internal and external validated next generation sequencing (NGS) panels are acceptable\n* Progressive disease (PD) after one previous standard of care line of treatment\n\n  * NOTE: symptoms from clinical evaluation for PD will be sufficient\n* Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1, measured preferably by computed tomography (CT) scan\n\n  * Note: Tumor lesions in a previously irradiated area are not considered measurable unless they show unequivocal progression\n  * NOTE: There is no limit on previous treatment lines\n* Patients who have received any neoadjuvant or systemic chemotherapy are eligible\n\n  * Note: treatment cannot have included prior pemetrexed unless in the case of non-small cell lung cancer (NSCLC) cancer type. Any prior intravesical therapy, or immunotherapy is allowed. At least 3 weeks (21 days) wash-out period from treatment since prior chemotherapy or radiation therapy or targeted agent is required\n* Patients must be aged ≥ 18 years\n* Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL (growth factor allowed and can be added at the discretion of the treating oncologist\n\n  * Growth factors are excluded from being used during the DLT observation period (cycle 1) unless they are being used to treat a grade 4 adverse event which will be counted as a DLT. If growth factors are being used for grade ≤ 3 toxicity, then patients will not be evaluable for DLT assessment\n* Hemoglobin (Hgb) ≥ 8.5 g\u002FdL (without the need for transfusion within the previous one week)\n* Platelets (PLT) ≥ 100,000\u002FmL (without the need for platelet transfusion within the previous one week)\n* Total bilirubin ≤ 1.5 x Institutional upper limit of normal (ULN), except subjects with Gilbert's syndrome or liver metastases, who must have a baseline total bilirubin ≤ 3.0 mg\u002FdL\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) ≤ 3 x institutional ULN or ≤ 5 x ULN if documented liver metastases are present\n* Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 x institutional ULN or ≤ 5 x ULN if documented liver metastases are present\n* Creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m\\^2 using the standard Cockcroft and Gault formula\n* Patients must have the ability to comply with folic acid, vitamin B12 and steroids as directed by study team and as per standard of care for pemetrexed use\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression\n* Pemetrexed is known to be teratogenic. Reproductive toxicology studies with MRTX1719 have not been performed. The investigator or designee shall counsel patients of childbearing potential (POCBP) participants and male (as assigned at birth) participants who are sexually active with POCBP on the importance of pregnancy prevention, the implications of an unexpected pregnancy, and the potential of fetal toxicity occurring due to transmission of study intervention present in seminal fluid to a developing fetus, even if the participant has undergone a successful vasectomy or if the partner is pregnant. If needed, participants should be advised to seek advice about egg or sperm donation and cryopreservation of germ cells before treatment\n\n  * Patients of childbearing potential POCBP\n\n    * A POCBP is any patient with an egg-producing reproductive tract who meets the following criteria:\n\n      * Has not undergone a hysterectomy or bilateral oophorectomy\n      * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n    * POCBP are not permitted to use hormonal contraceptive methods alone as a highly effective method of contraception and must use an additional non-hormonal highly effective method of contraception. POCBP must agree to use a combination of a hormonal and a non-hormonal contraceptive method or a non-hormonal method alone that is highly effective (with a failure rate of \\\u003C 1% per year) during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer\n    * POCBP participants must also agree not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period\n    * Male (as assigned at birth) participants will be required to always use a latex or other synthetic condom during any sexual activity (eg, vaginal, anal, oral) with POCBP, even if the participant has undergone a successful vasectomy or if the partner is pregnant or breastfeeding. Male (as assigned at birth) participants should continue to use a condom during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer\n    * POCBP partners of male (as assigned at birth) participants should be advised to use a highly effective method of contraception during the intervention period and for at least 6 months after the last dose of study intervention for the male participant, or according to approved local product label requirements for pemetrexed, whichever is longer\n    * Male (as assigned at birth) participants with a pregnant or breastfeeding partner must agree to remain abstinent from sexual activity or use a male condom during any sexual activity (eg, vaginal, anal, oral), even if the participant has undergone a successful vasectomy, during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer\n    * Male (as assigned at birth) participants must refrain from donating sperm during the intervention period and for at least 6 months after the last dose of study intervention, or according to approved local product label requirements for pemetrexed, whichever is longer\n    * Breastfeeding partners of male (as assigned at birth) participants should be advised to consult their health care provider about using appropriate highly effective contraception during the time the male participant is required to use condoms\n    * POCBP must have a negative pregnancy test prior to registration on study\n* The ability to interrupt nonsteroidal antiinflammatory drugs (NSAIDS) or aspirin at higher dose (\\> 1.3 g daily) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed\n\nExclusion Criteria:\n\n* STAGE I AND II, COHORT A (INCLUDING SAFETY RUN IN) AND B:\n* Patients who received prior pemetrexed containing chemotherapy (apart from NSCLC)\n* Patients with prior treatment with a PRMT5 or MAT2A inhibitor therapy\n* Patients with pre-existing clinically significant interstitial lung disease (ILD)\n* Patients who have had chemotherapy or radiotherapy ≤ 21 days prior to planned treatment start date.\n\n  * Note: seven days or fewer of palliative radiotherapy for non-CNS disease, is permitted. No wash-out is required\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia and neuropathy per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 5.0\n* Patients who are receiving any other investigational agents or devices. Patients start of study treatment will be based on their discontinuation and recovery from clinically significant adverse events from their most recent therapy or intervention prior to study enrollment\n* Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:\n\n  * Ongoing or active infection requiring systemic treatment\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification\n\n  * Note: To be eligible for this trial, patients should be class 2B or better\n* Patients with presence of third space fluid which cannot be controlled by drainage\n\n  * Note: For patients who develop or have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before or during initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing. However, if, in the investigator's opinion, the effusion represents progression of disease, the patient should be discontinued from study therapy\n* Patients who are not able to understand and voluntarily sign a written informed consent and is not willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures\n* Patients who are pregnant or nursing\n* Patients with history of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications\n* Patients with Fridericia's formula-corrected QT interval (QTcF) prolongation \\> 480 msec, except for right bundle branch block, per the investigator's assessment\n* Patients with ongoing need for a medication with a known risk of Torsade's de Pointes that cannot be switched to an alternative treatment prior to study entry\n* Patients with ongoing need for a medication known as a strong inhibitor or strong inducer of cytochrome P450 3A4 (CYP3A4) and\u002For P-glycoprotein (P-gp) or a proton-pump inhibitor and potassium-competitive acid blockers that cannot be switched to an alternative treatment prior to study entry\n\n  * NOTE: The following drug interaction databases and other literature can be utilized to determine the CYP3A4\u002FP-gp inhibitors and inducers\n  * Note: Please consult with the manufacturer for any uncertainties regarding potential CYP3A4 and P-gp modulators\n* Patients with inability to comply with restrictions and prohibited treatments\n* Patients taking any botanical preparation (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study within 4 weeks prior to treatment. The concurrent use of any botanical preparation is not permitted while on study\n* Patients with a known history of human immunodeficiency virus (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 6 months prior to registration. Please note this lab is not a requirement for eligibility, however, if it has been completed previously as part of the patient's health care, it should be documented for eligibility\n* Patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Please note this lab is not a requirement for eligibility; however if it has been completed previously as part of the patient's health care, it should be documented for eligibility\n* Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with a known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Please note this lab is not a requirement for eligibility; however if it has been completed previously as part of the patient's health care, it should be documented for eligibility\n* Patients who take live\u002Fattenuated vaccine received within 30 days of first treatment. The use of inactivated seasonal influenza vaccines (e.g., Fluzone®) will be permitted on study without restriction\n* Patient has not received the final dose of any of the following treatments\u002F procedures with the specified minimum intervals before first dose of study drug:\n\n  * Surgery with general anesthesia - within 7 days of first dose of study drug\n  * Surgery with local anesthesia - with 3 days of first dose of study drug",{"count":109,"type":20},72,[111,112],"PHASE1","PHASE2","This phase Ib\u002FII trial tests the safety and side effects of BMS-986504 in combination with pemetrexed and how well the combination works in treating patients with solid tumors with MTAP deletion and that has spread from where it first started (primary site) to other places in the body (metastatic). The MTAP gene helps cells recycle important parts needed to make deoxyribonucleic acid (DNA), which is needed for cell growth and function. MTAP deletion means that the MTAP gene is missing. BMS-986504, a PRMT5 inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill tumor cells. Giving BMS-986504 in combination with pemetrexed may be safe, tolerable, and\u002For effective in treating patients with metastatic solid tumors with MTAP deletion.",[115,116,117,118,119,120,121,122],"Metastatic Biliary Tract Carcinoma","Metastatic Colon Carcinoma","Metastatic Esophageal Carcinoma","Metastatic Malignant Digestive System Neoplasm","Metastatic Malignant Solid Neoplasm","Metastatic Pancreatic Carcinoma","Stage IV Colon Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8",{"date":70,"type":33},{"date":125,"type":20},"2027-12-09",{"date":127,"type":20},"2030-12-09",{"name":39,"class":40},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":41},"100649138","aromatherapy-and-music-impact-on-nurses-stress-at-work-100649138","NCT07732179","Aromatherapy and Music Impact on Nurses' Stress at Work","Inclusion Criteria:\n\n-CCU nurses at NM AMC providing direct patient care.\n\nExclusion Criteria:\n\n* currently pregnant\n* allergic to essential oils",{"count":7,"type":20},[55],"The purpose of the Doctor of Nursing Practice research project is to determine if nurses who receive chamomile-lavender aromatherapy and listen to music during a 20-minute break once per shift for 8 weeks, will experience report decreased work stress (measured by self-reported symptoms of anxiety) compared to before the aromatherapy and music intervention during breaks.\n\nThe investigators know nurses are at high risk for stress and anxiety. Despite the current processes and policies in place at Northwestern Memorial Hospital that support nurses to take breaks during their shifts, nurses continue to share feeling stressed and anxious. Included in this Doctor of Nursing Practice research project is an evidence synthesis of fourteen studies supporting the idea that combining aromatherapy and music can reduce anxiety in both adults and children.\n\nThe evidence-based intervention being studied is administering lavender-chamomile essential oil aromatherapy and listening to music during 20-minute non-meal breaks once a shift for 8 weeks. Participants will go to a quiet breakroom, pour 3 drops of lavender-chamomile essential oil onto a non-adhesive 2X2 gauze pad, and place the pad about 20 centimeters from their noses while also listening to their preferred calming music through their personal phones and wireless earbuds or headphones for twenty minutes.",[139],"Stress",[141,142,143],"nurse","aromatherapy","music","2026-08-17",{"date":30,"type":33},{"date":147,"type":33},"2026-07-01",{"date":149,"type":20},"2026-09-30",{"name":39,"class":40},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":41},"100596800","phase-2-cemiplimab-for-the-treatment-of-incurable-metastatic-or-unresectable-nut-carcinoma-100596800","NCT07050186","Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma","A Single Arm Open-Label Pilot Study to Investigate the Safety and Clinical Activity of Cemiplimab, A Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Incurable NUT Carcinoma (NC)","Inclusion Criteria:\n\n* Patients must have a histologically confirmed NUT carcinoma that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.\n* Patient may be treatment naïve or have had prior surgery, radiation, or any systemic therapy (with the exceptions noted in the Exclusion Criteria).\n* Patients must have histologically or cytologically confirmed NUT carcinoma based on the ectopic expression of NUT protein per World Health Organization (WHO) criteria as determined by immunohistochemistry (IHC) and\u002For detection of NUT gene translocation as determined by fluorescence in situ hybridization (FISH) at a Clinical Laboratory Improvement Act (CLIA) certified laboratory and\u002For by detection of the NUT gene translocation as determined by sequencing (e.g., deoxyribonucleic acid \\[DNA\\] next generation sequencing \\[NGS\\] or ribonucleic acid \\[RNA\\] sequencing) at a CLIA certified laboratory.\n* Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.\n* Patients must be age ≥ 18 years.\n* Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Leukocytes (WBC) ≥ 3,000\u002FmcL.\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL.\n* Hemoglobin (Hgb) ≥ 9 g\u002FdL.\n* Platelets (PLT) ≥ 100,000\u002FmcL.\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) ≤ 3 x institutional ULN.\n* Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) ≤ 3 x institutional ULN.\n* Creatinine ≤ 1.5 x institutional ULN.\n* Glomerular filtration rate (GFR) ≥ 40 mL\u002Fmin\u002F1.73 m\\^2.\n\n  * Estimated (e)GFR is estimated GFR calculated by the abbreviated Modification of Diet in Renal Disease (MDRD) equation.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy.\n* The effects of cemiplimab on the developing human fetus are unknown. For this reason and because immune checkpoint inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic, patients of child-bearing potential (POCBP) and their partners with sperm-producing reproductive capacity must agree to use adequate contraception from time of informed consent, for the duration of study participation, and for 6 months following completion of cemiplimab therapy. Should a POCBP become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately.\n\n  * NOTE: A POCBP is any patient (regardless of gender, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) with an egg-producing reproductive tract who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy\n    * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n* POCBP must have a negative pregnancy test prior to registration on study.\n* Patients with sperm-producing reproductive capacity (PWSPRC) treated or enrolled on this protocol must also agree to use adequate contraception with partners of childbearing potential from time of informed consent, for the duration of study participation, and for 6 months after completion of administration.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document prior to the start of any study activities (e.g. before screening\u002Fbaseline activities and before registration on the study) and comply with the study requirements.\n\nExclusion Criteria:\n\n* Prior treatment with PD-1 or PD-L1 inhibitors.\n* Received systemic therapy, radiation, or had surgery ≤ 14 days prior to planned treatment start date.\n\n  * NOTE: Prior therapy must meet requirements of criteria listed in Exclusion Criteria\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy, (i.e., have residual toxicities \\> grade 1 per National Cancer Institute \\[NCI\\] Common Terminology Criteria for Adverse Events \\[CTCAE\\] v5) with the exception of alopecia, neuropathy, and other non-significant adverse events.\n* Patients who are receiving any investigational agents or devices ≤ 14 days from planned start of treatment date.\n* History of allergic reactions or acute hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to immune checkpoint inhibitors and\u002For to antibody treatments.\n* Patients with a known history of Human immunodeficiency virus (HIV).\n\n  * NOTE: Infected patients on effective anti-retroviral therapy with an undetectable viral load for 6 months prior to start of study participation are eligible to participate.\n  * NOTE: CD4+ T cell counts and viral load are monitored per standard of care.\n* Patients with a known history of chronic hepatitis B virus (HBV) infection.\n\n  * NOTE: Patients with HBV and an undetectable viral load on suppressive therapy are eligible to participate.\n  * NOTE: CD4+ T cell counts, and viral load are monitored per standard of care.\n* Patients with a known history of hepatitis C virus (HCV) infection.\n\n  * NOTE: For patients with a known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load OR\n  * NOTE: Patients with an HCV infection must have been treated and cured in order to participate.\n  * NOTE: CD4+ T cell counts, and viral load are monitored per standard of care.\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:\n\n  * Hypertension that is not controlled on medication\n  * Ongoing or active infection requiring systemic treatment\n\n    * NOTE: Prophylactic antibiotic treatment is allowed (e.g. for uncomplicated infections such as urinary tract infections \\[UTIs\\] or sinus infections being treated with oral antibiotics)\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * History of pneumonitis within the last 5 years\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Patients have received a prior allogeneic stem cell transplant or received an organ transplant.\n* Patients have ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune mediated adverse events (imAEs).\n\n  * NOTE the following are not exclusionary:\n\n    * Vitiligo,\n    * Childhood asthma that has resolved,\n    * Type 1 diabetes,\n    * Residual hypothyroidism that required only hormone replacement,\n    * Psoriasis that does not require systemic treatment.\n    * And the following medications:\n\n      * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection);\n      * Systemic corticosteroids at physiologic doses ≤ 10 mg\u002Fday of prednisone or equivalent;\n      * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).\n* Patients that received prior treatment with other immune modulating agents that was:\n\n  * Less than 4 weeks (28 days) prior to the first dose of cemiplimab, or\n  * Associated with imAEs that were grade ≥ 1 within 90 days prior to the first dose of cemiplimab, or\n  * Associated with toxicity that resulted in discontinuation of the immune-modulating agent.\n* Patients of child-bearing potential (POCBP) who are pregnant or nursing.\n\n  * NOTE: POCBP that are pregnant or are nursing are excluded from this study; cemiplimab is an immune checkpoint inhibitor agent with potential for teratogenic or abortifacient effect. There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cemiplimab; breastfeeding should be discontinued if the patient is a nursing parent treated with cemiplimab.\n* Patient with a current or prior malignancy within the previous 2 years and in the opinion of the treating investigator would interfere with monitoring of radiological assessments of response to cemiplimab. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. Incidentally diagnosed prostate cancer is also allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.",{"count":159,"type":20},15,[112],"This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.",[163,164],"Metastatic NUT Carcinoma","Unresectable NUT Carcinoma",{"date":94,"type":33},{"date":167,"type":33},"2025-08-15",{"date":169,"type":20},"2035-11-20",{"name":39,"class":40},{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":16,"minAge":177,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":41},"100652743","central-auditory-processing-modulation-underlying-anxiety-reduction-using-clinically-designed-improvisatory-music-100652743","NCT07775625","Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music","Inclusion Criteria\n\n* Clinical diagnosis of Alzheimer's Disease\n* Positive Alzheimer's disease biomarkers (blood test, amyloid PET scan or CSF)\n* Mini-mental State Exam (MMSE) \\>=15\n* Rating for Anxiety in Dementia (RAID) score \\> 8\n\nExclusion Criteria\n\n* Significant hearing impairments\n* Major comorbidities Beck Depression Inventory (BDI) scores above \\> 10'","55 Years",{"count":179,"type":20},30,[55],"This study examines whether Clinically Designed Improvisatory Music (CDIM) can reduce anxiety in people living with Alzheimer's disease and anxiety (AD-A), and whether it can also lessen caregiver burden. CDIM is a live, receptive music-based intervention that uses slow tempi, simple diatonic melodic lines, soft dynamics, and periodic pauses to promote relaxation. As described in the proposal, CDIM has previously been shown to reduce stress and improve physiological markers such as heart rate, blood pressure, and EEG alpha\u002Fbeta ratios (CDIM significantly decreased physical stress symptoms and patients also reported positive emotional outcomes and EEG readings showed increased alpha\u002Fbeta brainwave ratios ).\n\nThe study will enroll 30 dyads (individuals with AD-A and their caregivers). Dyads will be randomly assigned to either CDIM or a control intervention (CI) consisting of calming short stories read aloud. Both interventions include eight 30-minute sessions over four weeks, delivered in alternating in-person and virtual formats.\n\nThe primary goal is to determine whether CDIM is feasible and effective in reducing anxiety in individuals with AD-A, measured by the Rating Anxiety in Dementia (RAID) scale, and in reducing caregiver burden, measured by the Zarit Burden Interview (ZBI). The study also evaluates changes in heart rate and blood pressure as indicators of autonomic regulation.\n\nA second goal is to explore whether CDIM improves central auditory processing, assessed using the frequency-following response (FFR). The proposal notes that central auditory processing declines with age and dementia and may contribute to anxiety. FFR will be measured before and after the intervention to determine whether CDIM enhances neural timing and response magnitude.\n\nOverall, this pilot study aims to determine whether CDIM is a feasible, safe, and potentially effective non-pharmacological intervention for reducing anxiety in individuals with AD-A and decreasing caregiver burden, while also investigating its underlying neurophysiological mechanisms.",[183],"Alzheimer's Disease",[185,186,187],"Music-based intervention","Anxiety","Alzheimer's disease","2026-08-16",{"date":70,"type":33},{"date":191,"type":33},"2026-02-02",{"date":193,"type":20},"2026-12-15",{"name":39,"class":40},{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100631243","procedural-framing-and-epidural-steroid-injection-outcomes-100631243","NCT07498140","Procedural Framing and Epidural Steroid Injection Outcomes","PEACE Study: Psychophysical Enhancement to Augment Conservative and Epidural Steroid Injection Outcomes: A Multi-Center International Randomized Trial","PEACE","Inclusion Criteria:\n\n* Age \\> 18\n* Lumbosacral radicular pain based on history and physical exam (e.g. pain radiating into one or both lower extremities, sensory loss, muscle weakness, positive straight leg raising test etc.)\n* Duration of pain \\>6 weeks\n* NRS leg pain score \\>\u002F= 4 (or if 3\u002F10, greater or equal to back pain \\& worst leg pain is \\>\u002F=4)\n* MRI evidence of spinal pathology consistent with symptoms\n* Candidates for ESI and pharmacotherapy\n\nExclusion Criteria:\n\n* Untreated coagulopathy\n* Previous spine surgery\n* No MRI or non-concordant MRI study\n* Leg pain \\> 15 years duration\n* Epidural steroid injection within past 2 years\n* Signs or symptoms of cauda equina syndrome\n* Previous failed trials with gabapentin and pregabalin and tricyclic antidepressants and duloxetine\n* Allergic reactions to contrast dye prohibiting injection (e.g., tranforaminal ESI), gabapentinoids, tricyclic antidepressants or duloxetine, and contraindications to all of the above medications\n* Referrals from surgery for diagnostic injections for surgical evaluation\n* Serious medical (e.g. congestive heart failure) or psychiatric (untreated depression) condition that might preclude optimal outcome\n* Pregnancy\n* Inability to understand basic English",{"count":204,"type":20},210,[55],"Back pain is the leading cause of disability and military medical boards across the globe. Epidural steroid injections (ESI) are the most commonly performed pain procedure in the world.\n\nThere is strong evidence that the placebo effect for all pain treatments, including ESI, is greater than the intrinsic effect. The placebo effect is highly dependent on a patient's 'expectations', and therefore how the procedure is framed.\n\nThis study aims to compare ESI when the procedure is framed very positively- as is often done in clinical practice vs. more neutrally (which is less commonly done in clinical practice but consistent with evidence). The placebo effect is also stronger for procedures than medications. The evidence on the benefits of ESI is highly dependent on whether it is compiled by interventional doctors who perform the procedure or non-interventional researchers.\n\nIn order to determine how 'framing' a treatment affects pain outcomes, the investigative team will conduct a 3-arm randomized trial comparing positive framing of ESI, neutral framing of ESI, and medications, in patients with lumbosacral radiculopathy.",[208],"Lumbosacral Radiculopathy",[210,211,212,213,214,215],"Back pain","Lumbar radiculopathy","Epidural steroid injection","Placebo effect","Sciatica","Positive framing","2026-08-14",{"date":94,"type":33},{"date":219,"type":33},"2026-03-30",{"date":221,"type":20},"2028-06-30",{"name":39,"class":40},4,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":41},"100627047","alcohol-neurolysis-and-capsaicin-for-postamputation-pain-pap-100627047","NCT07443553","Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP)","Randomized Controlled and Observational Studies Evaluating Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP)","Inclusion Criteria:\n\n* 1\\. Age \\>\u002F= 18 years 2. At least 1 lower extremity amputation 3. Pain duration \\>\u002F= 1 month 4. Either average RLP or PLP in one or both (for those who have 2 lower limbs enrolled) amputated extremities \\>\u002F=4\u002F10 5. Stable analgesic regimen over the past 10 days 6. Failure of physical therapy and at least 2 pharmacological treatments 7. At least 1 suspected painful neuroma, identified by Tinel's sign or pain with pressure or prosthetic use, referred pain in the distribution of the severed nerve, and neuropathic-type symptoms (tingling, shooting or lancinating pain)\n\nExclusion Criteria:\n\n* 1\\. Very poorly controlled psychiatric condition (e.g., PCL-5 score \\> 60, \\> 15 on the anxiety and\u002For depression section of HADS) 2. Poorly controlled medical condition that would preclude participation (e.g., heart failure, uncontrolled diabetes) 3. Patients in whom targeted muscle reinnervation or a similar procedure is being considered 4. Systemic infection or infection overlying the stump 5. Clinically-relevant injury to nerve fibers proximal to the amputation 6. Pregnancy",{"count":232,"type":20},120,[55],"Postamputation pain is a complex condition that includes phantom limb pain (PLP), stump pain and residual limb pain (RLP), the latter of which may be referred from joints, the spine and inflamed bursa and tendons. PLP may have peripheral, spinal and central etiologies. The evidence of peripheral mechanisms includes the relief of both PLP and RLP during local anesthetic (LA) infusions, the relief of PLP and RLP with sympathetic blocks and neuroma injections, and the development of phantom radicular pain in amputees with a herniated disc.\n\nNeurolysis and defunctionalization are long-lasting treatments for pain when LA blocks provide temporary benefit, being most commonly used for cancer pain (e.g., celiac plexus neurolysis). Neurolysis has also been used to treat PAP, with uncontrolled studies showing benefit for both RLP and PLP. However, there are no controlled studies demonstrating efficacy. In this small study, we will evaluate the effectiveness of alcohol neurolysis of lower extremity neuromas (femoral or saphenous; sciatic or common peroneal and\u002For tibial; obturator and\u002F or lateral femoral cutaneous when pain is in those distributions) in individuals with RLP and PLP.\n\nFor individuals with upper extremity amputation in whom non-selective neurolysis may affect the ability to use certain prosthetics that depend on functioning nerve and muscle signals, high-concentration capsaicin will be injected in an observational arm. The investigators will also examine factors associated with treatment outcome in a subset of patients (e.g., functional MRI, quantitative sensory testing).",[236],"Postamputation Pain",[238,239,240],"Postamputation pain","phantom limb pain","residual limb pain",{"date":94,"type":33},{"date":243,"type":20},"2026-10-31",{"date":245,"type":20},"2029-12-31",{"name":39,"class":40},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":258,"conditions":259,"keywords":264,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":159},"100615521","precision-medicine-in-achalasia-premedia---cohort-100615521","NCT07293689","PREcision MEDicine In Achalasia (PREMEDIA) - Cohort","PREcision MEDicine In Achalasia - A Multicenter Randomized Non-Inferiority Clinical Trial of Short Tailored POEM vs. Standard POEM for Non-Spastic Achalasia and A Multicenter Prospective Cohort Study of Long Tailored POEM for Spastic Esophageal Motility Disorders","PREMEDIA","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Type III achalasia or EGJOO with spastic\u002Fhypercontractile features or Jackhammer Esophagus or Distal Esophageal Spasm\n3. Eckardt Score \\> 3\n\nExclusion Criteria:\n\n* Exclusion:\n\n  1. Prior POEM\n  2. Prior surgical treatment for achalasia\n  3. Endoscopic pneumatic dilation or lower esophageal sphincter botulinum toxin (botox) injection within 6 months\n  4. Prior unrelated esophageal or upper gastric surgery, including Roux-en-Y gastric bypass and sleeve gastrectomy\n  5. Prior endoscopic gastroesophageal intervention for obesity or GERD, such endoscopic sleeve gastroplasty or transoral incisionless fundoplication\n  6. Known secondary achalasia related to malignancy (pseudoachalasia)\n  7. Known eosinophilic esophagitis\n  8. Diverticulum (\\> 2 cm) in distal esophagus\n  9. Megaesophagus\n  10. Fibroinflammatory stricture of the esophagus due to any etiology (e.g., peptic, radiation, eosinophilic)\n  11. Pregnancy\n  12. Standard contraindications to general anesthesia\n  13. Standard contraindications to endoscopic myotomy in the esophagus (e.g. untreated varices)\n  14. Unwillingness or inability to consent for the study\n  15. Anticipated inability to follow protocol",{"count":256,"type":20},200,"OBSERVATIONAL","The goal of this observational study is to learn about how the doctor decides how long to cut t the esophageal muscle during Per-Oral Endoscopic Myotomy (POEM) in patients with difficulty swallowing due to certain conditions. The main question it aims to answer is: does pre-POEM testing help the physician choose how long to cut the muscle.\n\nParticipants will allow researchers to access their standard of care information in their medical record, complete questionnaires at up to 6 times over a 2-year period.",[260,261,262,263],"Type III Achalasia","EGJ Outflow Obstruction With Spastic\u002FHypercontractile Features","Jackhammer Esophagus","Distal Esophageal Spasm",[265,266],"achalasia","EGJOO",{"date":144,"type":33},{"date":269,"type":20},"2026-12-01",{"date":271,"type":20},"2032-08-31",{"name":39,"class":40},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":252,"acronym":253,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":21,"phases":281,"briefSummary":283,"conditions":284,"keywords":288,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":159},"100615518","phase-3-precision-medicine-in-achalasia-premedia-100615518","NCT07293650","PREcision MEDicine In Achalasia (PREMEDIA)","Inclusion Criteria\n\n1. Age ≥ 18\n2. Type I achalasia or type II achalasia or cEGJOO\n3. Eckardt score \\> 3\n\nExclusion Criteria\n\nThe following exclusion criteria are for the RCT, but 1-13 below also pertain to the observational study:\n\n1. Prior POEM\n2. Prior surgical treatment for achalasia\n3. Endoscopic pneumatic dilation or lower esophageal sphincter botulinum toxin (botox) injection within 6 months\n4. Prior unrelated esophageal or upper gastric surgery, including Roux-en-Y gastric bypass and sleeve gastrectomy\n5. Prior endoscopic gastroesophageal intervention for obesity or GERD, such endoscopic sleeve gastroplasty or transoral incisionless fundoplication\n6. Known secondary achalasia related to malignancy (pseudoachalasia)\n7. Known eosinophilic esophagitis\n8. Diverticulum (\\> 2 cm) in distal esophagus\n9. Megaesophagus\n10. Fibroinflammatory stricture of the esophagus due to any etiology (e.g., peptic, radiation, eosinophilic)\n11. Pregnancy\n12. Standard contraindications to general anesthesia\n13. Standard contraindications to endoscopic myotomy in the esophagus (e.g. untreated varices)\n14. Unwillingness or inability to consent for the study\n15. Anticipated inability to follow protocol\n16. Weekly (or more frequent) opioid medication use in the last 2 years",{"count":280,"type":20},372,[282],"PHASE3","The goal of this clinical trial is to learn if shorter Per-Oral Endoscopic Myotomy (POEM) works as well as a longer POEM in patients with trouble swallowing due to certain conditions. The main question\\[s\\] it aims to answer \\[is\u002Fare\\]:\n\n* Does making a smaller cut in the muscle at the bottom of the esophagus work just as well as making the standard bigger cut in relieving symptoms?\n* Does making the smaller cut reduce the side effects of the procedure compared to the standard bigger cut? Researchers will compare the symptoms and side effects of making a shorter cut to the symptoms and side effects of a longer cut.\n\nParticipants will allow researchers to access their standard of care information in their medical record, complete questionnaires at up to 6 times over a 2-year period.",[285,286,287],"Type I Achalasia","Type II Achalasia","EGJ Outflow Obstruction Without Spastic\u002FHypercontractile Features",[265,266],{"date":144,"type":33},{"date":291,"type":33},"2026-04-29",{"date":293,"type":20},"2032-08-01",{"name":39,"class":40},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":41},"100605360","personalized-theta-burst-stimulation-for-long-lasting-changes-in-approachavoidance-behavior-100605360","NCT07161505","Personalized Theta-burst Stimulation for Long-lasting Changes in Approach\u002FAvoidance Behavior","The Efficiency of Personalized Theta-burst Stimulation for Inducing Long-lasting Changes in DLPFC","Inclusion Criteria:\n\n1. Participants must be legal adults between the ages of 18 to 65;\n2. Able and willing to complete study procedures and tasks.\n\nExclusion Criteria:\n\n1. History or evidence of chronic neurological or mental disorder;\n2. Chronic condition that requires pharmacological treatment over the course of study participation;\n3. Pregnancy or breastfeeding;\n4. History or evidence of alcohol or drug addiction;\n5. Contraindications for transcranial magnetic stimulation (history of seizures, metallic or electric implant in the head\u002Fneck area);\n6. Contraindications for magnetic resonance imaging at 3 Tesla (non-compatible implants, metallic foreign bodies, insulin pump, pacemaker).","65 Years",{"count":304,"type":20},26,[55],"This study will assess the long-lasting effects of personalized theta burst stimulation (TBS), a repetitive form of transcranial magnetic stimulation (TMS), over the left prefrontal cortex on the approach\u002Favoidance behavior. TBS will be personalized based on the prefrontal theta rhythm captured with electroencephalography (EEG). The main questions it aims to answer are: 1. does a single session of personalized TBS synchronized with the individual theta rhythm over the left prefrontal cortex results in the outlasting changes in the individual behavior? 2. Does TBS results in the brain rhythms' changes as measured using resting-state EEG?",[308],"Approach\u002FAvoidance Behavior",{"date":94,"type":33},{"date":311,"type":33},"2025-07-31",{"date":313,"type":20},"2027-02-28",{"name":39,"class":40},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":16,"minAge":321,"maxAge":302,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":41},"100575221","electrophysiological-representations-of-odor-in-the-human-brain-study-1-100575221","NCT06769464","Electrophysiological Representations of Odor in the Human Brain Study 1","Inclusion Criteria:\n\n* Ages 12 to 65, english speaker, patients undergoing brain surgery for treatment of medically intractable epilepsy\n\nExclusion Criteria:\n\n* screening for history of smell or taste problems","12 Years",{"count":323,"type":20},28,[55],"Investigating representations of odor intensity in human piriform cortex. To identify a neural representation of perceived odor intensity, it is necessary to dissociate stimulus concentration from perceived intensity. Experiments for this aim will measure human perceptual responses while manipulating intensity independently from concentration using two complementary approaches. In Experiment 1A, we will match perceived intensities across odors of different concentrations, allowing us to identify a neural representation of intensity that is independent of stimulus identity and concentration. In Experiment 1B, we will create conditions of different perceived intensity over constant odor stimuli using adaptation. Approaching the same question from different angles will strengthen the robustness of our findings. Preliminary data suggest that temporal features of the piriform neural response may represent odor intensity.",[327],"Odor Intensity Ratings",{"date":94,"type":33},{"date":330,"type":33},"2024-04-01",{"date":332,"type":20},"2028-08-01",{"name":39,"class":40},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":41},"100567321","early-phase-1-effect-of-neural-constraints-on-movement-in-stroke-100567321","NCT06666673","Effect of Neural Constraints on Movement in Stroke","ENCMS","Inclusion Criteria:\n\n* History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment\n* Age between 18-80\n* Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50\u002F66)\n* Ability to communicate, understand, and provide informed consent\n* Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension\n* MRI compatible\n* Intact skin on the hemiparetic arm\n* Ability to sit for three hours.\n\nExclusion Criteria:\n\n* Motor or sensory impairment in the non-affected limb (FMA\\\u003C66, filament \\>3.6)\n* Any brainstem and\u002For cerebellar lesion\n* untreated cardiovascular disease\n* History of neurologic disorder other than stroke that affects the arms\n* Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale\n* Current use of a pacemaker\n* History of seizure\n* Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol\u002Falcohol injections \\\u003C12 months before participation\n* Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes\n* Current participation in any experimental rehabilitation or drug studies\n* Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity\n* pregnant women or women who are nursing.\n\nAdditionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in \"Medication Interactions\", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive\u002F antiarrhythmic agents; and hormonal medications\u002Fcontraceptives.","80 Years",{"count":343,"type":20},64,[23],"This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.",[347],"Stroke",[349,350,351,352,353,354,355],"Neurotransmitters","flexion synergy","brain plasticity","tizanidine","stroke","motor control","spasticity",{"date":94,"type":33},{"date":358,"type":33},"2024-08-23",{"date":360,"type":20},"2029-07-31",{"name":39,"class":40},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":16,"minAge":369,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":41},"100649943","medication-collaboration-feasibility-study-100649943","NCT07742189","Medication Collaboration Feasibility Study","Feasibility Study of a Brief Intervention to Support Medication Collaboration Among Older Adults and Family Care Partners","Inclusion Criteria for older adults with dementia:\n\n1. Age 60 or older\n2. Diagnosis of dementia, Alzhimer's Disease or Mild Cognitive Impairment\n3. Quick Dementia Rating Scale Score 2-12 (inclusive of mild cognitive impairment and mild dementia)\n4. Taking 3 or more medications\n5. Involved with managing their medications\n6. Proficient speaking English\n7. Capacity to provide consent\n\nInclusion criteria for caregivers include::\n\n1. Primary family caregiver for the past 3 months\n2. Age 18 or older\n3. Proficient speaking English\n\nExclusion Criteria:\n\n* adults unable to consent","60 Years",{"count":179,"type":20},[55],"This study examines the feasibility and acceptability of a brief medication collaboration intervention among older adults (age 60+) with early-stage dementia or mild cognitive impairment who take multiple medications and their family caregivers. The main aims are to: 1) determine the feasibility and acceptability of the intervention for older adults with early-stage dementia and their family caregivers, and 2) explore the effects of intervention on medication collaboration, medication adherence, and beliefs about dementia and autonomy.\n\nIn this study, participants will: 1) complete a 15-30-minute baseline interview (by Zoom or phone), 2) participate together in a 45-60-minute virtual intervention led by an interventionist that includes:\n\nAssessment of medication responsibilities and beliefs. Education about dementia and medication management. Cognitive restructuring to address beliefs about independence and caregiver assistance.\n\nCollaborative planning for medication responsibilities and routines; and lastly 3) complete a 15-20-minute one-month follow-up interview (by Zoom or phone) to assess the intervention's acceptability and changes in medication management outcomes.",[374,375,376],"Dementia Family Caregiver","Dementia","Medication Adherence","2026-08-13",{"date":216,"type":33},{"date":380,"type":33},"2026-08-03",{"date":382,"type":20},"2026-12",{"name":39,"class":40},{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":83,"minAge":17,"maxAge":341,"enrollmentInfo":391,"targetDuration":4,"studyType":21,"phases":392,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":404,"locationsCount":4},"100634297","phase-2-efficacy-of-intracavernosal-xeomin-with-tadalafil-for-mild-moderate-erectile-dysfunction-100634297","NCT07537855","Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction","Clinical Efficacy of Intracavernosal Xeomin as an Adjunctive Therapy to on Demand Tadalafil 20 mg for the Treatment of Mild to Moderate Erectile Dysfunction: A Randomized Crossover Pilot Study","Inclusion Criteria:\n\n* Written informed consent obtained from the subject\n* History of ED for at least 6 months prior to screening, defined as \"the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse\" (NIH), the diagnosis of ED has to be confirmed by a physician\n* Understanding of study procedures and willingness to abide by all procedures during the course of the study\n* Male subject aged ≥18 to ≤ 80 years at visit 1\n* Have a monogamous relationship with a female sexual partner (vaginal penetration required for several of the primary efficacy variables) for at least 6 months prior to screening\n* Highly motivated to obtain treatment for ED\n* History of previous use of at least 1 marketed PDE5 inhibitor and insufficient therapeutic efficacy despite use of the highest approved dose\n\nExclusion Criteria:\n\n* Hypersensitivity to the active substance (Clostridium Botulinum neurotoxin type A) or to any of the excipients (Human albumin, sucrose)\n* BW \\\u003C50 kg\n* Diagnosis of spinal cord injury\n* ED caused by other primary sexual disorders including premature ejaculation or ED caused by untreated endocrine disease (e.g., hypopituitarism, hypothyroidism, or hypogonadism)\n* History of penile implant.\n* The presence of clinically significant penile deformity in the opinion of the investigator.\n* Concomitant diagnosis of Peyronie's disease\n* Patients with chronic stable angina treated with long-acting nitrates, or patients with chronic stable angina who have required short-acting nitrates in the last 90 days, or angina occurring during sexual intercourse in the last 6 months.\n* Patients having met the criteria for unstable angina within 6 months prior to Visit 1, history of myocardial infarction or coronary artery bypass graft surgery within 90 days prior to Visit 1, or percutaneous coronary intervention (e.g., angioplasty or stent placement) within 90 days prior to Visit 1.\n* Any supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate \\>100 bpm) at rest despite medical or device therapy, or any history of spontaneous or induced sustained ventricular tachycardia (heart rate \\>100 bpm for 30 sec) despite medical or device therapy, or the presence of an automatic internal cardioverter-defibrillator.\n* A history of sudden cardiac death (arrest) despite medical or device therapy.\n* Any evidence of congestive heart failure within 6 months prior to Visit 1.\n* A significant conduction defect within 90 days prior to Visit 1.\n* Systolic blood pressure \\>170 or \\\u003C90 mm Hg or diastolic blood pressure \\>100 or \\\u003C50 mm Hg at screening (if stress is suspected, retest under basal conditions), or patients with malignant hypertension.\n* \\\u003C12 weeks since most recent injection of BTX-A\u002FB into any body region for any indication\n* Neurological disorder associated with neuro muscular dysfunction of any kind in medical history.\n* Planned concomitant treatment with BTX -A\u002FB of any body region during the study.\n* Known hypersensitivity to human serum albumin, sucrose, or the active substance BTX-A.\n* Generalized disorders of muscles activity (e.g. myasthenia gravis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis) or any other significant peripheral neuromuscular dysfunction which might interfere with the study.\n* Any condition that would interfere with the patient's ability to provide informed consent or comply with study instructions, would place patient at increased risk, or might confound the interpretation of the study results.\n* Current treatment with nitrates (as outlined in previous Exclusion Criterion, cancer chemotherapy, or anti-androgens.\n* History of drug, alcohol, or substance abuse within the past 6 months.\n* Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.\n* Treatment within the last 30 days with a drug or device that has not received regulatory approval at the time of study entry.\n* Ongoing severe or uncontrolled systemic disease, current malignancy, hemophilia, or HIV infection in medical history.\n* Severe or uncontrolled respiratory disease in medical history.\n* Evidence or suspicion that the subject is not willing or unable (e.g. Due to severe cognitive communication impairment) to understand the information that is given to him as part of the informed consent, in particular regarding the risks and discomfort which he would agree to be exposed to.\n* Any reason which in the investigator's opinion is likely to compromise the subject's ability to participate in the study.\n* Subject who is imprisoned or is lawfully kept in an institution\n* Participation in a clinical study within 12 weeks prior to screening or planned participation during this study.\n* Previous participation in this clinical study.",{"count":179,"type":20},[112],"Erectile dysfunction (ED) affects approximately 30 million men in the United States and is associated with factors such as aging, smoking, diabetes, hypertension, obesity, and sedentary lifestyle. ED can also negatively impact the quality of life of patients and their partners. Treatment decisions are typically made jointly between patients and their urologists, often starting with less invasive options. Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors), including sildenafil, tadalafil, and vardenafil, are commonly used as first-line therapy. While these medications improve erectile function in many patients, approximately 30-40% do not respond adequately to PDE5 inhibitor therapy alone. Patients who do not achieve sufficient benefit may require additional or more invasive treatment options.",[395],"Erectile Dysfunction",[397,398],"xeomin","Incobotulinumtoxin A","2026-08-12",{"date":216,"type":33},{"date":402,"type":20},"2026-09",{"date":74,"type":20},{"name":39,"class":40},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":16,"minAge":369,"maxAge":412,"enrollmentInfo":413,"targetDuration":4,"studyType":21,"phases":415,"briefSummary":416,"conditions":417,"keywords":421,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":429},"100524755","otc-hearing-aid-and-mci-100524755","NCT06112860","OTC Hearing Aid and MCI","Over-the-counter Hearing Aids and Mild Cognitive Impairment","Inclusion Criteria:\n\n* Over 60 years of age\n* Mild dementia or mild cognitive impairment. Diagnosis will be made at participating memory evaluation centers (see recruitment).\n* Mild to moderate bilateral hearing loss and no current hearing aid use.\n* A communication partner who is able and willing to participate in the study.\n* No vision impairment that would interfere with the ability to complete study tasks (i.e., legally blind, severe cataracts, or macular degeneration)\n* Able to provide own consent as evaluated by the Consent Assessment\n\nExclusion Criteria:\n\n1. Clinically significant unstable or progressive medical conditions, or conditions which, in the opinion of the investigator(s) places the participant at unacceptable risk if he or she were to participate in the study.\n2. History of unresolved communication difficulties following another neurological problem (i.e., stroke or brain tumor), neurodevelopmental disorder (i.e., Down's syndrome), or head\u002Fneck cancer\n3. Positive history of major psychiatric disorder (i.e., schizophrenia, significant untreated depression)\n4. Co-enrolled in other intervention studies targeting hearing, language, or communication strategies.\n5. History or current fluctuating hearing loss","90 Years",{"count":414,"type":20},50,[55],"The goal of this study is to better understand if, in patients with mild to moderate hearing loss who are also experiencing mild cognitive impairment (MCI) or Alzheimer's disease and related dementias (ADRD), Over-the-Counter (OTC) hearing aids:\n\n1. improve communication\n2. Whether the magnitude of benefit depends on the patient's level of cognitive disability,\n3. Whether alternative remediation (such as targeted communication strategies) offer similar benefits.\n\nParticipants and a communication partner will be randomized into an OTC first or Communication Strategies first arm, where participants will receive communication strategy information customized for those with cognitive impairment.",[418,419,420],"Hearing Loss","Mild Cognitive Impairment","Alzheimer Disease and Related Dementias (ADRD)",[422],"Over-the-counter Hearing Aids",{"date":216,"type":33},{"date":425,"type":33},"2024-07-23",{"date":427,"type":20},"2027-03-30",{"name":39,"class":40},3,{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":21,"phases":438,"briefSummary":439,"conditions":440,"keywords":445,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":41},"100505680","phase-2-phase-2a-immune-modulation-with-ultrasound-for-newly-diagnosed-glioblastoma-100505680","NCT05864534","Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","A Phase 2a Trial of Immune Modulation in Combination With Ultrasound-mediated Blood Brain Barrier Opening in Patients With Newly Diagnosed Glioblastoma","Inclusion Criteria:\n\n* Have newly diagnosed pathologically proven glioblastoma, isocitric dehydrogenase-1\u002F2 wild-type\n* Tumor with methyl guanine methyl transferase (MGMT) gene promoter unmethylated\n* Available paraffin embedded tumor tissue for the study\n* Have completed standard radiotherapy with or without temozolomide\n* 18 years of age or older\n* Able to undergo contrast-enhanced MRI\n* Have an Eastern Cooperative Oncology Group\u002FWorld Health Organization performance status ≤ 2\n* Size and location of the residual tumor and\u002For resection cavity must allow to be able to be covered by the sonication field\n* Have not received any prior treatment with immunotherapeutic agents treatments for glioblastoma or other indications\n* Have the ability to understand and willingness to sign a written informed consent prior to registration on study.\n* Be willing and able to comply with the protocol.\n* Have adequate organ and bone marrow function\n* Agree to use adequate contraception if appropriate\n\nExclusion Criteria: Patients will be ineligible if they have:\n\n* Multifocal tumor (unless all localized in a 50-mm diameter area accessible to ultrasound field) or tumor located in the posterior fossa.\n* Uncontrolled epilepsy.\n* Received other investigational agents within 2 weeks of registration\n* Received prior therapy with or have history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study.\n* Contraindication to checkpoint inhibitor therapy (e.g., history of autoimmune disease)\n* Uncontrolled illness\n* History of active malignancy other than the brain tumor within 12 months prior to registration.\n* Are pregnant or breastfeeding.",{"count":7,"type":20},[112],"Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain. If the BBB can be opened, making it temporarily more permeable, drugs may able to better reach the brain tumor. In this trial we will implant a novel device with 9 ultrasound emitters, allowing temporary and reversible opening of the BBB to maximize brain penetration of drugs that modulate the immune system. The device will be implanted after radiation is completed. Immune modulating drugs will be given every 3 weeks in conjunction with activation of the device to open the BBB.\n\nThe objectives of this trial are to establish whether it is safe and feasible to administer immune modulating drugs in this manner, and identify whether the treatment is effective in treating glioblastoma.",[441,442,443,444],"Newly Diagnosed Glioblastoma","Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype","Gliosarcoma","Glioblastoma Multiforme",[446,447,448,449,450,451,452],"Immunotherapy","Ultrasound","Blood-brain barrier","Sonocloud","Balstilimab (BAL)","Botensilimab (BOT)","Doxorubicin (DOX)",{"date":216,"type":33},{"date":455,"type":33},"2024-01-19",{"date":457,"type":20},"2031-08-31",{"name":39,"class":40},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":21,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":484},"100624328","early-phase-1-sleep-dreaming-and-virtual-reality-for-mental-health-100624328","NCT07408206","Sleep, Dreaming, and Virtual Reality for Mental Health","Transformative Benefits of Contemplative Sleep Practices and a Novel Pathway to Deliver Benefits to the General Public","Inclusion Criteria:\n\n* Individuals interested in participating will be screened for eligibility through a Qualtrics survey, a Score between 5-21 points in GAD-7.\n\nHealthy, English-speaking adults (at least 18 years old) with high dream recall (at least 1\u002Fweek).\n\nExclusion Criteria:\n\n* We will exclude people who self-report any of the following:\n\n  1. history of an established meditative practice\n  2. psychological or psychiatric disorders (other than mild anxiety)\n  3. sleep disorders, nightshift work in the past month, extreme chronotype or irregular sleeping pattern\n  4. use of recreational drugs in the past month\n  5. history of asthma, seizures or heart problems\n  6. unwillingness to wear headband during sleep",{"count":467,"type":20},70,[23],"People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking. Recent advances in sleep monitoring, dream communication, and lucid dream induction now make it possible to study these practices using scientific methods.\n\nThis study is a randomized controlled trial designed to examine the feasibility and effects of a Dream-Yoga-inspired intervention compared with an active control condition. The intervention combines waking and dreaming practices that are adapted for individuals without prior experience and delivered using virtual reality-based training and home sleep technology. The program is designed to be scalable and culturally neutral, without requiring prior knowledge of contemplative or religious traditions.\n\nThe primary goals of the study are to characterize sleep and waking neurophysiology associated with Dream-Yoga-inspired practices and to evaluate whether participation is associated with changes in sleep-related brain activity and cognitive processes. Outcomes include measures of lucid dreaming, sleep physiology, and waking cognitive and perceptual processes. Anxiety will be assessed as an exploratory outcome to examine whether participation may be associated with changes in emotional experience. This study is not designed to provide treatment for anxiety or other clinical conditions.\n\nResults from this study will help inform the development of scalable sleep-based mental training approaches and guide future research on the use of dreaming and sleep practices to support psychological health and well-being.",[186],[472,473,474,475,476],"lucid dreaming","dream yoga","contemplative practices","meditation","mind-body interventions","2026-08-11",{"date":377,"type":33},{"date":480,"type":33},"2026-01-15",{"date":482,"type":20},"2027-12-31",{"name":39,"class":40},2,{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":302,"enrollmentInfo":493,"targetDuration":4,"studyType":21,"phases":495,"briefSummary":496,"conditions":497,"keywords":500,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":508},"100605736","phase-2-valproic-acid-for-traumatic-brain-injury-trial-100605736","NCT07166393","Valproic AcId for Traumatic BRAin INjury Trial","Multi-institutional Phase 2\u002F3 Trial of Valproic Acid in Patients With Moderate to Severe Traumatic Brain Injury","VIBRANT","Inclusion Criteria:\n\n1. Male or female between the ages of 18 and 65 years.\n2. Body Mass Index between 18 kg\u002Fm2 and 35 kg\u002Fm2.\n3. Females must be surgically sterilized, postmenopausal, or have a negative urine pregnancy test.\n4. Moderate to severe TBI: Glasgow Coma Scale (GCS) 3-12.\n5. Cerebral trauma confirmed on the initial CT scan with radiographic findings consistent with Brain Injury Guidelines category 3 (BIG 3) criteria\n\nExclusion Criteria:\n\n1. Persons with known history of adverse reactions to VPA\n2. Persons with known history of hepatitis B or C or clinical history of hepatic dysfunction, pancreatitis, or renal insufficiency.\n3. Persons with a known history of thrombocytopenia.\n4. Persons with platelet count less than 100,000 per microliter of blood.\n5. Persons with 2nd or 3rd degree burns of any size and location.\n6. Female subjects who are pregnant or lactating.\n7. Persons who are currently incarcerated or are in police custody.\n8. Persons with inadequate venous access.\n9. Treatment cannot start within 120 minutes from the onset of injury\n10. Non-survivable injuries in the estimation of the attending trauma surgeon.\n11. Interfacility transfers\n12. The time of injury is unknown\n13. Patients in hemorrhagic shock with a systolic blood pressure of \\\u003C90 mmHg on initial evaluation.\n14. Persons with a known \"do not resuscitate\" order prior to randomization\n15. Persons with a research \"opt out\" bracelet\n16. Persons who are currently enrolled in another clinical trial.\n17. Greater than 90 minutes between the onset of injury and arrival to the hospital",{"count":494,"type":20},432,[112,282],"The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI).\n\nPatients with moderate to severe TBI will randomly receive either:\n\n1. Standard of care treatment and normal saline\n2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose",[498,499],"Moderate Traumatic Brain Injury (TBI)","Severe Traumatic Brain Injury",[501],"TBI, traumatic brain injury, VPA, valproic acid",{"date":377,"type":33},{"date":504,"type":20},"2027-05",{"date":506,"type":20},"2031-12",{"name":39,"class":40},8,{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":517,"conditions":518,"keywords":523,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":530,"locationsCount":41},"100648937","effects-of-axatilimab-on-skin-in-chronic-graft-versus-host-disease-100648937","NCT07728708","Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease","Mapping On-Target Effects of Axatilimab in Human Chronic Graft-versus-Host Disease Skin: A Prospective Observational Mechanistic Study","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosis of chronic graft-versus-host disease (cGVHD) with skin involvement.\n* Planned initiation of axatilimab as part of routine clinical care (axatilimab arm) or not planning initiation of axatilimab as part of routine clinical care (control arm).\n* Able to undergo a skin biopsy at the time of enrollment.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Unable to provide informed consent.\n* Contraindication to skin biopsy, including severe thrombocytopenia or other conditions that make skin biopsy unsafe in the judgment of the investigator.\n* Active uncontrolled infection.",{"count":159,"type":20},"Chronic graft-versus-host disease (cGVHD) is a condition that can develop after a stem cell transplant. It occurs when donor immune cells attack the body's tissues. In many people, cGVHD affects the skin, causing inflammation, thickening, and scarring that can limit movement and reduce quality of life.\n\nAxatilimab is a medicine approved by the U.S. Food and Drug Administration (FDA) to treat adults with cGVHD after at least two previous treatments have not worked well enough. Although axatilimab can improve cGVHD, researchers do not fully understand how it changes immune cells in the skin.\n\nThe purpose of this study is to learn how axatilimab affects immune cells in the skin and blood of people with cGVHD. Researchers will study skin and blood samples collected before and after participants start axatilimab. The goal is to better understand how the medicine reduces inflammation and scarring and to identify biological changes that occur during treatment.\n\nThis is an observational research study. The study does not decide whether participants receive axatilimab, when treatment starts, or what dose they receive. All treatment decisions are made by the participant's treating physician as part of routine medical care.\n\nAbout 15 adults with cGVHD involving the skin will participate. Ten participants who are starting axatilimab as part of their usual care will have three study visits: before treatment begins, about 2 weeks after starting treatment, and about 12 weeks after starting treatment. At each visit, participants will provide a small skin biopsy and a blood sample. Five participants with cGVHD who are not receiving axatilimab will serve as a comparison group and will complete one study visit with one skin biopsy and one blood sample. Researchers will also review participants' medical records and collect information about their skin disease over time.\n\nInformation from this study may help researchers better understand how axatilimab works in people with cGVHD. The findings may also help improve future research and guide the development of treatments for cGVHD and other diseases that cause tissue scarring.",[519,520,521,522],"Chronic Graft vs. Host Disease","GVHD","cGVHD","Graft Versus Host Disease in Skin",[521,520,524],"axatiliamab","2026-08-09",{"date":399,"type":33},{"date":528,"type":20},"2026-10",{"date":37,"type":20},{"name":39,"class":40},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":21,"phases":540,"briefSummary":541,"conditions":542,"keywords":545,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":41},"100623141","aldh2-genetic-testing-in-east-asian-community-100623141","NCT07392775","ALDH2 Genetic Testing in East Asian Community","A Community-Based Approach for ALDH2 Genetic Testing in East Asian Americans","Inclusion Criteria:\n\n1. Age 18 or older\n2. Self-identified as East Asian and\u002For East Asian American\n3. Flush when they drink alcohol or have a family member who flushes when they drink\n4. Able to read and speak English",{"count":539,"type":20},100,[55],"The goal of this clinical trial is to learn whether education plus genetic testing for ALDH2\\*2 and ADH1B\\*2 is feasible and acceptable and whether it influences modifiable health behaviors in East Asian American adults who experience alcohol flushing when they drink alcohol or have a family history of flushing. The main questions it aims to answer are:\n\n1. Is providing education plus ALDH2\\*2\u002FADH1B\\*2 genetic testing feasible and acceptable in a clinical care context?\n2. Does receiving genetic testing results plus education lead to changes in modifiable health behaviors compared with education alone? Researchers will compare education plus genetic testing (intervention arm) to education only (control arm) to see if adding genetic testing improves feasibility\u002Facceptability and supports health behavior change.\n\nParticipants will:\n\n1. Complete an education module about alcohol flushing and ALDH2\u002FADH1B\n2. Be randomized to either: (A) Receive genetic testing for ALDH2\\*2 and ADH1B\\*2 with results disclosure, or (B) Receive education only.\n3. Complete follow-up measures about feasibility, acceptability, and modifiable health behaviors",[543,544],"Healthy Adult","Flushing",[546,547,548,549,550,551,183,552],"East Asian","Alcohol Flushing","ALDH2","ADH1B","Esophageal Cancer","Genetic Testing","Cardiovascular Disease","2026-08-07",{"date":477,"type":33},{"date":556,"type":20},"2026-11-01",{"date":558,"type":20},"2029-06-30",{"name":39,"class":40},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":567,"enrollmentInfo":568,"targetDuration":570,"studyType":257,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":581},"100588311","optimal-adult-heart-transplant-immunosuppression-with-microrna-levels-100588311","NCT06939751","OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels","OPTIMAL","Inclusion Criteria:\n\n* Age ≥ 18 years at enrollment\n* Receipt of orthotopic heart transplant (OHT) within the prior 1 month ± 2 weeks\n* Planned follow-up at the transplant center for a minimum of one-year.\n* Patient able and willing to comply with the study visit schedule, study procedures, and study requirements.\n\nExclusion Criteria:\n\n* Recipient of a multi-organ transplant\n* History of prior solid organ transplant before the index heart transplant\n* Ongoing mechanical circulatory support or hemodynamic instability (e.g., inotrope or vasopressor therapy)\n* Ongoing need for renal replacement therapy and\u002For dialysis\n* Active infection requiring either a) hospitalization b) treatment with antimicrobial therapy or c) reduction in immunosuppression\n* Active rejection being treated with intravenous medications or plasmapheresis","99 Years",{"count":569,"type":20},250,"3 Years","This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels). These miRs will be used to characterize the overall immune state in adult heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.",[573,574],"Cardiac Failure","Graft Rejection",{"date":477,"type":33},{"date":577,"type":33},"2025-10-28",{"date":579,"type":20},"2032-01-01",{"name":39,"class":40},6,{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":589,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":593,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":581},"100557036","optimal-pediatric-heart-transplant-immunosuppression-with-micrornas-100557036","NCT06532890","Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs","OPTIMA","Inclusion Criteria:\n\n* Age ≤ 18 years at time of transplant listing\n* Subject is within 10-50 days post-orthotopic heart transplant at time of enrollment.\n* Planned follow-up at the transplant center for a minimum of one-year.\n* Caregiver able and willing to comply with the study visit schedule, study procedures, and study requirements.\n\nExclusion Criteria:\n\n* Recipient of a multi-organ transplant\n* History of prior solid organ transplant before the index heart transplant\n* Ongoing mechanical circulatory support or hemodynamic instability after transplant\n* Active infection requiring either a) hospitalization or b) treatment with antimicrobial drugs (does not include prophylaxis for infection or suppressive antibiotics given after transplant)\n* History of treated rejection prior to study enrollment\n* Inability to collect specified blood volume after enrollment and prior to 50 days post-transplant",{"count":590,"type":20},150,"This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.",[573,574],{"date":477,"type":33},{"date":595,"type":33},"2025-02-06",{"date":597,"type":20},"2029-10-01",{"name":39,"class":40},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":83,"minAge":606,"maxAge":607,"enrollmentInfo":608,"targetDuration":4,"studyType":21,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":41},"100530732","combination-intervention-to-enhance-treatment-engagement-and-viral-suppression-among-sexual-and-gender-minority-youth-in-nigeria-100530732","NCT06190613","Combination Intervention to Enhance Treatment Engagement and Viral Suppression Among Sexual and Gender Minority Youth in Nigeria","Adapting and Testing a Combination Peer Navigation and mHealth Intervention to Enhance Treatment Engagement and Viral Suppression Among Sexual and Gender Minority Youth in Nigeria","Inclusion Criteria:\n\n* HIV seropositive\n* registered as a patient at one of the collaborating key population (KP)-focused community centers\n* male sex at birth\n* identify as YMSM or YTW (or report a history of sex with men)\n* understand and read basic English, Yoruba, or Pidgin English\n* intention to remain a patient at a collaborating clinic during the 24-week follow-up period\n* has a cellphone\n\nExclusion Criteria:\n\n* Unable to obtain parental permission if 15 years of age and not emancipated","15 Years","29 Years",{"count":609,"type":20},110,[55],"The study will adapt and test a combination peer navigation and mHealth approach, Intensive Combination Approach to Rollback the Epidemic in Nigeria (iCARE Nigeria), to improve HIV treatment engagement, medication adherence and viral suppression among YMSM and YTW, ages 15-29.",[613],"HIV","2026-08-06",{"date":553,"type":33},{"date":617,"type":33},"2024-11-28",{"date":619,"type":20},"2026-12-31",{"name":39,"class":40},""]